Do You Seek and Do You Use Molecular Marker Information in Patients with Early Stage NSCLC?

Do You Seek and Do You Use Molecular Marker Information in Patients with Early Stage NSCLC?

From: GRACEcast
0 0 7 years ago
00:00
01:37
Medicine, #adjuvant, #cancergrace, #early, #erlotinib, #grace, #gracecast, #karen, #kelly, #nsclc, #radiant, #stage, #tarceva, #targeted, #therapy, #ucdavis
Dr. Karen Kelly of University of California, Davis, presents her current view on using molecular markers in early stage non-small cell lung cancer and explains the RADIANT study that she leads.

Author

cancerGRACE Meetings
cancerGRACE Meetings 2 followers Follow

Find us on Facebook

Spreaker logo
  • Choose Language

For Podcasters and Editors

Tools for Podcasters

For Listeners

Copyright 2021 - Spreaker Inc. a Voxnest Company - Create a Podcast - New York, NY